|
Synonyms: CL-297939 | EMD-33512 | Zebeta®
bisoprolol is an approved drug (FDA (1992))
Compound class:
Synthetic organic
Comment: Bisoprolol is a β-blocker, selective for β1-adrenoceptors in cardiac tissue. The S(-) enantiomer is believed to account for most of its β-blocking activity.
Marketed formulations may contain bisoprolol fumarate (PubChem CID 6917733). Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. Baker JG. (2005)
Evidence for a secondary state of the human beta3-adrenoceptor. Mol Pharmacol, 68 (6): 1645-55. [PMID:16129733] |
|
2. Baker JG. (2005)
Site of action of beta-ligands at the human beta1-adrenoceptor. J Pharmacol Exp Ther, 313 (3): 1163-71. [PMID:15716385] |
|
3. Baker JG. (2005)
The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol, 144 (3): 317-22. [PMID:15655528] |
|
4. Baker JG. (2026)
Comparing the Molecular Pharmacological Properties of Existing β-Blockers to Determine the Theoretically Most "Ideal" Anti-Cancer β-Blocker. Pharmacol Res Perspect, 14 (1): e70214. [PMID:41485077] |
|
5. Baker JG, Gardiner SM, Woolard J, Fromont C, Jadhav GP, Mistry SN, Thompson KSJ, Kellam B, Hill SJ, Fischer PM. (2017)
Novel selective β1-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease. FASEB J, 31 (7): 3150-3166. [PMID:28400472] |
|
6. Baker JG, Kemp P, March J, Fretwell L, Hill SJ, Gardiner SM. (2011)
Predicting in vivo cardiovascular properties of β-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses. FASEB J, 25 (12): 4486-97. [PMID:21865315] |
|
7. Baker JG, Proudman RG, Hill SJ. (2013)
Impact of polymorphic variants on the molecular pharmacology of the two-agonist conformations of the human β1-adrenoceptor. PLoS One, 8 (11): e77582. [PMID:24250787] |
|
8. Baker JG, Proudman RG, Hill SJ. (2014)
Identification of key residues in transmembrane 4 responsible for the secondary, low-affinity conformation of the human β1-adrenoceptor. Mol Pharmacol, 85 (5): 811-29. [PMID:24608857] |
|
9. Lim VJY, Proudman RGW, Monteleone S, Kolb P, Baker JG. (2023)
The Isoleucine at Position 118 in Transmembrane 2 Is Responsible for the Selectivity of Xamoterol, Nebivolol, and ICI89406 for the Human β1-Adrenoceptor. Mol Pharmacol, 103 (2): 89-99. [PMID:36351797] |
|
10. Smith C, Teitler M. (1999)
Beta-blocker selectivity at cloned human beta 1- and beta 2-adrenergic receptors. Cardiovasc Drugs Ther, 13 (2): 123-6. [PMID:10372227] |
|
11. Sykes DA, Jiménez-Rosés M, Reilly J, Fairhurst RA, Charlton SJ, Veprintsev DB. (2022)
Exploring the kinetic selectivity of drugs targeting the β1 -adrenoceptor. Pharmacol Res Perspect, 10 (4): e00978. [PMID:35762357] |